

**S6 Table.** Reported accompanying other malignancies in primary pancreatic cancer patients

Accompanying other malignancies	Kamisawa et al. [1] (45/270, 16.6%)	Kasumi et al. [2] (9/123, 7.3%)	Yoshimori et al. [3] (12/111, 10.8%)	Makino et al. [4] (134/2394, 5.6%)	Tagawa et al. [5] (7/599, 1.17%)	Muller et al. [6] (16/1178, 1.36%)	Eriguchi et al. [7] (12)	Total
Stomach	15	5	-	26	-	-	5	51
Colorectal	6	-	1	9	-	-	4	20
Lung	3	-	-	10	7	-	2	22
Thyroid	9	-	1	25	-	-	-	35
Liver	2	-	-	3	-	-	-	5
Breast	5	1	-	5	-	-	-	11
Bladder	1	-	3	4	-	-	-	8
Prostate	3	1	1	14	-	-	-	19
Kidney	-	-	-	7	-	16	-	23
Appendix	-	-	-	-	-	-	-	0
Small intestine	-	-	-	-	-	-	-	0
CBD	-	-	-	-	-	-	-	0
Gallbladder	-	-	-	4	-	-	-	4
Testis	-	-	-	-	-	-	-	0
Uterus	1	1	2	9	-	-	1	14
Esophagus	2	-	1	2	-	-	-	5
Larynx	1	-	-	2	-	-	-	3
Tonsil	-	1	-	-	-	-	-	1
Salivary gland	-	-	-	-	-	-	-	0
Gingiva	1	-	1	-	-	-	-	2
Pharynx	-	-	2	1	-	-	-	3
Ovary	-	-	-	2	-	-	-	2

MFH	2	-	-	-	-	-	-	-	2
Melanoma	1	-	-	-	-	-	-	-	1
MM	-	-	-	1	-	-	-	-	1
AML	1	-	-	-	-	-	-	-	1
CML	1	-	-	1	-	-	-	-	2
Skin	-	-	-	1	-	-	-	-	1

CBD, common bile duct; MFH, malignant fibrous histiocytosis; Melanoma, malignant melanoma; MM, multiple myeloma; AML, acute myelocytic leukemia; CML, chronic myelocytic leukemia.